The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods

American Journal of Hypertension

Volumn 10, Issue 7 I, 1997, Pages 705-713

  Dahlof, B ^a   Devereux, R ^a   De Faire, U ^a   Fyhrquist, F ^a   Hedner, T ^a   Ibsen, H ^a   Julius, S ^a   Kjeldsen, S ^a   Kristianson, K ^a   Lederballe Pedersen, O ^a   Lindholm, L H ^a   Nieminen, M S ^a   Omvik, P ^a   Oparil, S ^a   Wedel, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Angiotensin II blocker; Atenolol; Cardiovascular; Hypertension; Intervention; Losartan; Mortality morbidity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; RAMIPRIL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0030872646     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00054-X     Document Type: Note

References (57)